Skip to main content

Table 1 Patient characteristics in the high-MIF and the low-MIF group

From: Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF)

  Entire cohort, n = 62 MIF ≤ 51.58 ng/ml, n = 31 MIF > 51.58 ng/ml, n = 31 p value
Clinical data
 Age, yearsa 73.5 (21.0) 71.0 (23.0) 77.0 (22.0) 0.026
 Male gender 26 (41.9) 14 (45.2) 12 (38.7) 0.80
 BMI (kg/m2) 27.9 (4.6) 28.3 (4.9) 27.5 (4.3) 0.47
 SBP (mmHg)a 132.5 (23.8) 132.0 (24.0) 133.0 (32.0) 0.21
 DBP (mmHg) 72.5 (13.5) 73.9 (13.4) 71.0 (13.7) 0.48
 Dyspnea NYHA III/IV 36 (58.1) 11 (35.5) 25 (80.6) < 0.001
Comorbidities
 AF 32 (51.6) 13 (41.9) 19 (61.3) 0.13
 CHD 34 (54.8) 13 (41.9) 21 (67.7) 0.041
 Hypertension 48 (77.4) 23 (74.2) 25 (80.6) 0.54
 Diabetes mellitus 16 (25.8) 6 (19.4) 10 (32.3) 0.25
 CKD 24 (38.7) 13 (41.9) 11 (35.5) 0.60
 COPD 11 (17.7) 3 (9.7) 8 (25.8) 0.10
Medication
 Betablocker 51 (82.3 26 (83.9) 25 (80.6) 0.74
 MRA 17 (27.4) 10 (32.3) 7 (22.6) 0.39
 ACE inhibitor 33 (53.2) 19 (61.3) 14 (45.2) 0.20
 Diuretics 45 (72.6) 21 (67.7) 24 (77.4) 0.39
 Oral anticoagulants 30 (48.4) 12 (38.7) 18 (58.1) 0.13
Echocardiographic parameters
 EF (%) 56.5 (5.5) 56.3 (5.7) 56.7 (5.5) 0.78
 LVEDD, cm 4.9 (0.8) 5 (0.6) 4.8 (0.9) 0.27
 PASP (mmHg)a 36.0 (22.8) 31.0 (20.0) 48.0 (20.0) 0.0017
 LAA (cm2) 24.4 (7.2) 22.6 (5.2) 26.2 (8.6) 0.06
Laboratory values
 WBC (cells/nl)a 6.7 (2.8) 6.2 (2.4) 7.1 (2.3) 0.11
 Hemoglobin (g/dl) 12.3 (1.5) 12.6 (1.3) 12.4 (1.8) 0.59
 Creatinine (mg/dl)a 1.2 (0.5) 1.2 (0.7) 1.2 (0.4) 0.65
 Urea (mg/dl)a 21.0 (11.0) 20.0 (12.0) 22.0 (10.0) 1.00
 LDH (U/l)a 248.0 (88.5) 236.0 (70.0) 261.0 (119.0) 0.038
 CRP (mg/dl)a 0.49 (1.2) 0.49 (0.51) 0.49 (1.2) 0.25
 BNP (pg/ml)a 229.8 (284.0) 134.4 (246.1) 298 (367.8) 0.0014
 NT-proBNP (pg/ml)a 1329.0 (3608.8) 612.0 (1397.0) 2517.0 (3644.0) 0.005
  1. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, NYHA New York Heart Association, AF atrial fibrillation, CHD coronary heart disease, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, MRA mineralocorticoid receptor antagonist, ACEI angiotensin converting enzyme inhibitor, EF ejection fraction, LVEDD left ventricular end-diastolic diameter, PASP pulmonary artery systolic pressure, LAA left atrial area, WBC white blood cells, LDH lactate dehydrogenase, CRP c-reactive protein, BNP b-type natriuretic peptide, NT-proBNP amino-terminal pro-b-type natriuretic peptide
  2. aValues represent median (interquartile range)